Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;10(3):272-85.
doi: 10.2174/157015912803217288.

NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease

Yu-Jhen Huang  1 , Chieh-Hsin Lin, Hsien-Yuan Lane, Guochuan E Tsai
Affiliations

NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease

Yu-Jhen Huang et al. Curr Neuropharmacol. 2012 Sep.

Abstract

Dementia has become an all-important disease because the population is aging rapidly and the cost of health care associated with dementia is ever increasing. In addition to cognitive function impairment, associated behavioral and psychological symptoms of dementia (BPSD) worsen patient's quality of life and increase caregiver's burden. Alzheimer's disease is the most common type of dementia and both behavioral disturbance and cognitive impairment of Alzheimer's disease are thought to be associated with the N-methyl-D-aspartate (NMDA) dysfunction as increasing evidence of dysfunctional glutamatergic neurotransmission had been reported in behavioral changes and cognitive decline in Alzheimer's disease. We review the literature regarding dementia (especially Alzheimer's disease), BPSD and relevant findings on glutamatergic and NMDA neurotransmission, including the effects of memantine, a NMDA receptor antagonist, and NMDA-enhancing agents, such as D-serine and D-cycloserine. Literatures suggest that behavioral disturbance and cognitive impairment of Alzheimer's disease may be associated with excitatory neurotoxic effects which result in impairment of neuronal plasticity and degenerative processes. Memantine shows benefits in improving cognition, function, agitation/aggression and delusion in Alzheimer's disease. On the other hand, some NMDA modulators which enhance NMDA function through the co-agonist binding site can also improve cognitive function and psychotic symptoms. We propose that modulating NMDA neurotransmission is effective in treating behavioral and psychological symptoms of Alzheimer's disease. Prospective study using NMDA enhancers in patients with Alzheimer's disease and associated behavioral disturbance is needed to verify this hypothesis.

Keywords: D-serine; glycine transporter; memantine; sarcosine..

PubMed Disclaimer

References

    1. Thies W, Bleiler L. Alzheimer's disease facts and figures. Alzheimer's & dementia. J. Alzheimer's Ass. 2011;7(2):208–44. - PubMed
    1. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15(5):365–75. - PubMed
    1. Ritchie K, Kildea D. Is senile dementia "age-related" or "ageing-related"?--evidence from meta-analysis of dementia prevalence in the oldest old. Lancet. 1995;346(8980):931–4. - PubMed
    1. Ferri C P, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–2117. - PMC - PubMed
    1. Brodaty H, Breteler M M, Dekosky S T, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg P A, Scheltens P, De Strooper B. The world of dementia beyond 2020. J. Am. Geriatr. Soc. 2011;59(5):923–7. - PubMed